Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NAARDEN, THE NETHERLANDS AND MIAMI, DEC. 05, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 40,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO TWO NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NAARDEN, THE NETHERLANDS AND MIAMI, NOV. 25, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN DECEMBER

NAARDEN, THE NETHERLANDS AND MIAMI, NOV. 07, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 18,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO ONE NON-EXECUTIVE NEW HIRE. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

 MARKETING AUTHORIZATION APPLICATIONS FOR OBICETRAPIB AND FDC OF OBICETRAPIB PLUS EZETIMIBE ACCEPTED FOR REVIEW BY EUROPEAN MEDICINES AGENCY 

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS

NAARDEN, THE NETHERLANDS AND MIAMI, OCT. 30, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT ADDITIONAL SAFETY AND EFFICACY DATA FROM THE PIVOTAL PHASE 3 BROOKLYN, BROADWAY AND TANDEM TRIALS AT THE 2025 AMERICAN HEART ASSOCIATION (AHA) SCIENTIFIC SESSIONS, TAKING PLACE NOVEMBER 7  10, 2025 IN NEW ORLEANS, LOUISIANA.

NEWAMSTERDAM PHARMA TO PARTICIPATE IN UPCOMING MEDICAL MEETING AND INVESTOR CONFERENCES IN NOVEMBER

FIRST-TIME PRESENTATION EXAMINING BONE OUTCOMES IN EARLY POSTMENOPAUSAL WOMEN FIRST-TIME PRESENTATION EXAMINING BONE OUTCOMES IN EARLY POSTMENOPAUSAL WOMEN

ENTERA BIO TO PRESENT NEW CLINICAL DATA FROM PHASE 2 TRIAL OF EB613 AT THE 2025 NORTH AMERICAN MENOPAUSE SOCIETY (NAMS) ANNUAL MEETING

NAARDEN, THE NETHERLANDS AND MIAMI, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V.

NEWAMSTERDAM PHARMA TO PRESENT AT THE STIFEL 2025 VIRTUAL CARDIOMETABOLIC FORUM

NAARDEN, THE NETHERLANDS AND MIAMI, AUG. 25, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT ADDITIONAL POOLED SAFETY AND EFFICACY DATA FROM THE PIVOTAL PHASE 3 BROADWAY AND BROOKLYN TRIALS AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS (ESC), TAKING PLACE AUGUST 29  SEPTEMBER 1, 2025 IN MADRID, SPAIN.

NEWAMSTERDAM PHARMA TO PARTICIPATE IN UPCOMING MEDICAL MEETING AND INVESTOR CONFERENCES IN SEPTEMBER

THE MULTI-MILLION-DOLLAR INVESTMENT PROVIDES NEWAMSTERDAM PHARMA WITH COMMERCIAL CAPACITY FOR FIXED DOSE COMBINATION (FDC) OF OBICETRAPIB AND EZETIMIBE TO MEET POTENTIALLY HIGH COMMERCIAL DEMAND. PIRAMAL PHARMA SOLUTIONS HARNESSED THE STRENGTH OF TWO ADDITIONAL FACILITIES TO EFFICIENTLY PRODUCE THE FDC, DEMONSTRATING THE ADVANTAGES OF ITS INTEGRATED APPROACH TO DEVELOPMENT.

PIRAMAL PHARMA SOLUTIONS AND NEWAMSTERDAM PHARMA INVEST IN DEDICATED SUITE TO ENHANCE ORAL SOLID DOSAGE PRODUCTION CAPABILITIES AT PIRAMAL'S SELLERSVILLE, PENNSYLVANIA SITE

-- FILINGS BOTH FOR THE OBICETRAPIB MONOTHERAPY AND OBICETRAPIB PLUS EZETIMIBE FIXED-DOSE COMBINATION SUBMITTED TO EMA BY OUR PARTNER, MENARINI, FOR TREATMENT OF ADULTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) OR MIXED DYSLIPIDEMIA -- -- NEWAMSTERDAM ENTITLED TO TIERED DOUBLE-DIGIT PERCENTAGE ROYALTIES RANGING FROM THE LOW DOUBLE-DIGITS TO MID-TWENTIES ON NET SALES IN THE MENARINI TERRITORY AND UP TO AN ADDITIONAL 833 MILLION UPON THE ACHIEVEMENT OF VARIOUS CLINICAL, REGULATORY AND COMMERCIAL MILESTONES --

NewAmsterdam Pharma Company N.V.

NAMS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NewAmsterdam Pharma Company N.V.

NAMS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NAMS